Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab induction chemoimmunotherapy followed by surgery or concurrent chemoradiotherapy for locally advanced pulmonary lymphoepithelioma-like carcinoma
ChiCTR2600132740Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pulmonary lymphoepithelioma-like carcinoma (PLELC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year event-free survival rate. Started Nov 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
pulmonary lymphoepithelioma-like carcinoma (PLELC)
Beyond the preview
Go deeper on ChiCTR2600132740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132740.